Carglumic Acid Brand Name– Carbaglu
What is Carglumic Acid
Carglumic acid (Carbaglu) is an oral treatment for acute and chronic hyperammonemia due to N-acetylglutamate synthase deficiency.
Plasma ammonia concentrations may be reduced the first day of treatment and may remain reduced.
Among 13 patients, carglumic acid was used daily for a mean of 8 years (range, 1—16 years); the median plasma ammonia concentration was 157 (range, 72—1428) at baseline, was 65 (range, 25—1190) on day 1, was 25 (range, 12—42) on day 3, and was 24 (range, 9—34) on the last value obtained on treatment.
Carglumic acid was designated as an orphan drug for the treatment of N-acetylglutamate synthase deficiency in 1998 and was approved by the FDA for the same indication in March 2010.
- N-acetylglutamate synthase deficiency
- abdominal pain
- weight loss
- plasma ammonia concentrations
There are no drug interactions associated with Carglumic Acid products.